Confirm Safety and Performance of Avance Solo and Avance Solo Adapt NPWT Systems

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-14

Study Completion Date

2023-07-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this post market clinical follow-up (PMCF) investigation is to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt NPWT Systems in low to moderate exuding chronic wounds when used in accordance with the Instructions for Use, for up to 28 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Confirm the Safety and Performance of Avance Solo NPWT System

NCT04754048

Acute Wound Traumatic Wound Skin Graft +3 more

COMPLETED NA

Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen

NCT01968811

Open Abdomen

COMPLETED NA

Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System

NCT05805046

Surgical Wound, Recent Surgical Wound Leak Dehiscence Wound +1 more

WITHDRAWN

Clinical Investigation of Two Different Wound Dressings

NCT02904200

Wounds and Injuries

TERMINATED NA

The Avelle® Negative Pressure Wound Therapy System on Chronic Wounds

NCT05666570

Diabetic Foot Ulcer Venous Leg Ulcer

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This investigation is designed as a prospective, open and non-comparative PMCF investigation to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt in low to moderate exuding chronic wounds. This is a multi-center study that will take place in approximately 5 European countries. The target subjects are male or female, 18 years or older with low to moderate exuding chronic wounds (pressure ulcers (N=68), diabetic foot ulcers (N=34), and venous leg ulcers (N=34)) suitable for NPWT as deemed by the investigator. Two different options of Negative Pressure Wound Therapies (NPWT) will be evaluated through this clinical investigation

A total of 136 subjects will receive treatment with the investigational devices within the intended use according to Instructions for Use (IfU): Group 1: 102 subjects in total, 34 subjects per indication (pressure ulcers, diabetic foot ulcers, and venous leg ulcers) treated with Avance®Solo and Group 2: 34 subjects with pressure ulcers treated with Avance®Solo Adapt. Subjects will be managed and monitored for a maximum of 4 weeks or until withdrawal from investigation for any reason.

The primary performance endpoint will include assessment of wound progress compared to last visit during a maximum 28 days investigation period. Wound progression is determined by the Investigator and will take into account all aspects of wound characteristics. Wound progression will be assessed by the Investigator at each follow-up visit and measured by three outcomes:

* Deteriorated
* No change
* Improved

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer Pressure Ulcer Diabetic Foot Ulcer Chronic Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Four different patient groups treated with the Avance Solo NPWT System or Avance Solo Adapt NPWT System.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Avance Solo NPWT System

Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.

Group Type EXPERIMENTAL

Avance Solo NPWT System

Intervention Type DEVICE

Wound treatment with Avance Solo NPWT System for up to 28 days.

Avance Solo Adapt NPWT System

Treatment with negative pressure wound therapy for Pressure ulcers.

Group Type EXPERIMENTAL

Avance Solo Adapt NPWT System

Intervention Type DEVICE

Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avance Solo NPWT System

Wound treatment with Avance Solo NPWT System for up to 28 days.

Intervention Type DEVICE

Avance Solo Adapt NPWT System

Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female ≥ 18 years.
2. Signed written informed consent.
3. Low to moderate exuding chronic wounds (diabetic foot ulcers, venous leg ulcers and pressure ulcers for Avance®Solo or pressure ulcers for Avance®Solo Adapt) suitable for NPWT according to the investigator´s judgement and Instructions for Use.
4. Subjects that will be capable and willing to comply with protocol instructions

Exclusion Criteria

1. Known malignancy in the wound or margins of the wound
2. Untreated and previously confirmed osteomyelitis
3. Non-enteric and unexplored fistulas
4. Necrotic tissue with eschar present
5. Exposed nerves, arteries, veins or organs
6. Exposed anastomotic site
7. Known allergy/hypersensitivity to the dressing or its components.
8. Known pregnancy or planning to become pregnant or lactation at time of study participation.
9. Participation in another investigative drug or device trial currently or within the last 30 days Subjects not suitable for the investigation according to the Investigator's judgement, Clinical Investigation Plan and Instructions for Use

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No